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Summary Taurolidine, the active agent of Taurolin®, is a
broad spectrum anti-biotic that has been used for over
15 years for the treatment of severe surgical infections.
Recently, taurolidine has been shown to possess anti-
neoplastic properties in vitro and in vivo against a variety
of cancers including ovarian, colon and prostate. In this
study we assessed the cytotoxic activity of taurolidine
against human osteosarcoma (OS) cell lines and normal
human bone cells. Treatment with taurolidine inhibited the
growth of all ten osteosarcoma cell lines tested and
taurolidine was equally potent against cell lines with and
without distinct genetic defects (i.e. p53, Rb). Moreover,
taurolidine-induced growth inhibition was found to be
associated with a dose dependent increase in the number of
apoptotic cells and apoptosis was shown to be caspase-
dependent. Taurolidine treatment was also found to inhibit
adhesion of OS cell lines. Compared to OS cell lines, normal
bone cells in primary culture were found to be less sensitive
to the cytotoxic and anti-adhesive effects of taurolidine.
These data indicate that taurolidine possesses potent anti-
neoplastic activity against osteosarcoma cell lines and may
have potential as a novel OS chemotherapeutic agent.
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Introduction
Osteosarcoma (OS) is a highly malignant bone tumor that
typically affects children and young adolescents between 10
and 20 years of age. Prior to 1970, surgical amputation was
the sole treatment for osteosarcoma and 5 year survival rates
were less than 20% [1]. Introduction of multi-agent adjuvant
chemotherapy in the early 1980s dramatically improved
survival rates and today administration of neo-adjuvant and
adjuvant chemotherapy is able to achieve 5 year survival
rates up to 70% for patients with non-metastatic disease
(reviewed in [2]). Despite this success no further increase in
survival has been achieved in over 10 years despite the
evaluation of several regimens incorporating various combi-
nations of approved chemotherapeutic agents (i.e. metho-
trexate, doxorubicin, cisplatin, etoposide, ifosphamide). In
addition, patients who relapse following standard chemo-
therapy have no additional chemotherapeutic options at the
present time. The mechanism of action of currently approved
chemotherapeutic agents is non-specific and consequently
their use is associated with a number of serious side-effects
including cardio-toxicity, nephrotoxicity, hearing loss and the
development of secondary malignancies. Consequently, the
discovery of novel chemotherapeutic agents with lower
toxicity and comparable or superior efficacy to current
agents is essential for the treatment of OS.
Taurolidine [bis (1,1-dioxoperhydro-1,2,4-thiabiazin-4-yl)
methane], the active component of Taurolin®, is a synthetic
anti-biotic and anti-fungal agent that has been used for over
15 years for the treatment of severe surgical infections and
local wound and bone infections [3–6]. Although the exact
mechanism underlying taurolidine’s anti-bacterial and anti-
fungal properties has yet to be elucidated, taurolidine’s
activity is thought to depend upon the interaction of active
methylol breakdown products with cell membrane compo-
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nents [7–9]. In addition to its anti-bacterial, anti-fungal and
anti-endotoxin properties taurolidine has also been shown to
possess potent anti-neoplastic activity in vitro against a
number of tumor cell lines including ovarian, colon, glioma
and melanoma [10–13]. Taurolidine treatment was also
shown to significantly decrease tumor burden in a murine
model of human ovarian carcinoma and in a model of
malignant mesothelioma [10, 14]. Intravenous administration
of taurolidine in patients with advanced glioblastoma and no
further chemotherapeutic options showed partial tumor
regression and extended survival time [15]. Taken together,
these data suggest that taurolidine has potential as a
chemotherapeutic agent for the treatment of patients suffering
from diverse types of malignancies. Consequently, we were
interested in assessing the potential anti-neoplastic effects of
taurolidine on human osteosarcoma cell lines in vitro.
Materials and methods
Cell lines and reagents
Human SAOS-2 (HTB-85), U2OS (HTB-96), HOS and
143B cells were obtained from the American Type Culture
Collection (ATCC, Rockville, MD). LM5 cells were provided
by E.S. Kleinerman (M.D. Anderson Cancer Center, Hous-
ton, TX). Hu09 WT, Hu09 H3 and Hu09 L13 cells were
provided by Dr. M. Tani (National Cancer Center Hospital,
Tokyo, Japan), MG-63 cells were provided Dr. G. Sarkar
(Mayo Clinic, Rochester, MN, USA) and MG-63 M8 cells
were provided by Dr. W.T. Zhu (Tongji Hospital, Huazhong
University of Science and Technology, Wuhan, China).
Normal fibroblasts were obtained from Coriell Cell Repos-
itories (Camden, NJ, USA). All cell lines, with the exception
of Hu09 WT, Hu09 H3 and Hu09 L13, were cultured in
Dulbecco’s Modified Eagle Medium (4.5 g/l glucose)/Ham
F12 (1:1) (Invitrogen, Carlsbad, CA) supplemented with 10%
FCS, 1 unit/ml penicillin G, and 1 μg/ml streptomycin. Hu09
WT, Hu09 H3 and Hu09 L13 cells were maintained in RPMI
supplemented with 10% FCS, 1 unit/ml penicillin G, and
1 μg/ml streptomycin. All cells were cultured at 37°C in a
humidified atmosphere of 5% CO2. The pan caspase
inhibitor, Z-VAD-FMK, was purchased from BD Pharmin-
gen (San Diego, CA). Taurolidine was generously provided
by Geistlich Pharma, Switzerland. Rat tail collagen type 1
was obtained from Sigma (St. Louis, MO, USA) and DAPI
was obtained from Molecular Probes (Eugene, OR, USA).
Normal human bone cell culture
Trabecular bone pieces (0.2–0.5 cm edge length), obtained
from surgical waste of patients undergoing total knee
arthroplasty, were washed several times with cell culture
medium supplemented with penicillin/streptomycin/ampho-
tericin (PSA;1:100, Invitrogen, Carlsbad, CA) until the
supernatant was clear and free of fat. Ten to twenty pieces
were then plated in a 10 cm dish and medium was changed
every second day to remove newly appearing fat for 1 week.
After further culture for 1–2 weeks a confluent monolayer
of outgrowing cells was obtained (E1). After harvesting by
trypsinization cells were expanded and passaged yielding
E1P1 and E1P2 cells. A second round of explant (E2) of
the same bone pieces yielded E2P1 and E2P2 cells. P1 or
P2 cells from E1 or E2 were used for the experiments.
Cytotoxicity assays
Cells were plated in 96-well plates (3,000 cells/well) and
allowed to adhere overnight. Various concentrations of
taurolidine were added the following day and cells were
incubated with taurolidine for either 24 or 72 h. Cytotox-
icity was measured by adding 10 μl of WST-1 reagent
(Roche, Mannheim, Germany) and incubating for 3 h.
WST-1 reagent is a membrane permeable tetrazolium salt
that undergoes cleavage via cellular enzymes in intact
living cells. The resulting cleavage product is formazan.
Thus, a change in the number of viable cells results in a
corresponding change in the amount of formazan dye
produced. Quantification of formazan dye was determined
by measuring dye absorbance with a scanning multiwell
spectrophotometer (Bio-Rad, Basel, Switzerland) at
415 nm. Percentage growth inhibition was determined by
dividing the absorbance of taurolidine treated cell results
by that of control (untreated) cells and multiplying by
100. Statistical differences were determined using the
Student’s T-test.
Detection of apoptosis
Apoptosis was assessed using an annexin V-FITC apopto-
sis detection kit and necrotic cells were determined by
Propidium Iodide (PI) staining (BD Pharmingen San
Diego, CA). 150,000 cells were plated in each well of a
6-well plate. Cells were allowed to adhere overnight and
indicated taurolidine concentrations were added the fol-
lowing day. Twenty-four hours later the cell culture
medium was removed and cells were washed 1× with
PBS and 1× with annexin binding buffer. Cells were then
incubated for 15 min with annexin binding buffer
containing annexin-V-FITC and PI. The cells were then
washed 1× and visualized using a Nikon Eclipse E600
microscope (Egg, Switzerland) equipped with a 10×
objective, a Nikon Y-FL fluorescence illumination with
appropriate filters and a Kappa DX20 camera (Kappa
opto-electronics GmbH, Gleichen, Germany).
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Immunoblotting
Cells (1×106) were lysed on ice with lysis buffer containing
50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% DOC,
0.1% SDS. Lysates were cleared of insoluble material by
centrifugation at 14,000 rpm for 10 min. Protein quantifi-
cation was determined using a standard Bradford assay and
80 μg of total protein was resolved by SDS-PAGE.
Resolved proteins were then transferred to Immobilon-P
membranes for immunoblotting. Poly-ADP-ribose polymer-
ase (PARP) and actin were detected using a PARP antibody
(Cell Signaling Technology, Beverly, MA) and an actin
antibody, respectively, (Chemicon, Dietikon, Switzerland)
and HRP secondary antibodies (Cell Signaling Technology,
Beverly, MA).
Adhesion
Cells were detached with PBS, 0.05% EDTA, transferred to
cell culture medium and counted in a Neubauer chamber.
After adjustment of cell number to 50,000 cells per ml, 1 ml
was added to a 6-well plate containing 1 ml of freshly
prepared 2-fold concentrated taurolidine, and coated over-
night with 20 μg (1 ml) per well with rat tail collagen type
1. Cells were then allowed to adhere for 15 min at 37°C,
washed twice with cell culture medium and once with PBS.
After fixation with 10% formalin for 15 min cell nuclei
were stained with 300 nM DAPI (Molecular Probes) and
random pictures (4–8 per well) were taken with a Nikon
Eclipse E600 microscope equipped with a Kappa camera
using a 10× objective corresponding to an area of 1.8 mm2.
Nuclei counting was performed with the freely available
ImageJ software (http://rsb.info.nih.gov/ij/).
Results
Taurolidine inhibits the growth of osteosarcoma cell lines
In initial experiments we examined whether taurolidine
exerted a growth inhibitory effect on osteosarcoma cell
lines. Incubation with taurolidine for 72 h resulted in growth
inhibition of all ten OS cell lines tested and the half-maximal
inhibitory concentration (IC50) of taurolidine ranged from 29
to 64 μM (Fig. 1a). Although certain OS cell lines are
known to possess distinct genetic defects [i.e. (SAOS-2-p53
deficient, truncated Rb) [16]], inhibition of the OS cell lines
was found to be independent of the presence or absence of
these defects. Moreover, cell lines possessing greater in vivo
metastatic potential (Hu09 H3, LM5, MG-63 M8, 143B)
than their parental cell lines (Hu09 WT, SAOS-2, MG-63
WT, HOS, respectively) were also found to be taurolidine
sensitive. Of note, although 143B and MG-63 M8 cells were
found to be taurolidine sensitive the IC50 was found to be
higher than their parental cell lines. Based on the fact that
Rodak et al (2005) [12] demonstrated that taurolidine can
exert cytotoxic effects on glioma cells as early as 24 h
following exposure, we also assessed the cytotoxic effect of
taurolidine on OS cell lines after 24 h (Fig. 1a). The half-
maximal inhibitory concentration of taurolidine following a
24 h treatment ranged from 28 to 95 μM.
Given the potent cytotoxic and anti-adhesive effects of
taurolidine on osteosarcoma cells we also wanted to
determine if taurolidine would have similar effects on cells
obtained from bone explants or normal human bone cells
and normal fibroblasts. Indeed, taurolidine inhibited the
growth of normal bone cells and normal fibroblasts.
However, the IC50 of taurolidine for normal bone cells
and normal fibroblasts was approximately three times
higher than those for OS cell lines suggesting that these
cells are less sensitive to the growth inhibitory effects of
taurolidine (Fig. 1a). The dose-response curves for the
osteosarcoma cell line U2OS, normal bone cells and normal
fibroblasts are shown in Fig. 1b. Due to the fact that the
effect of taurolidine appeared to be similar among all OS
cell lines tested, U2OS cells were used as a representative
cell line for all further experiments examining the effects of
taurolidine on OS cell lines.
Taurolidine induces apoptosis of OS cell lines
Translocation of phosphatidylserine (PS) to the cell surface is
an early indicator of apoptosis and annexin-V binds to PS with
high affinity [17]. To address whether taurolidine was
inducing apoptosis of OS cell lines we treated U2OS cells
with increasing concentrations of taurolidine for 24 h and
then stained PS on the surface of cells with annexin-V-FIT-C.
Necrotic cells were detected by PI staining. As shown in
Fig. 1c, exposure of U2OS cells to increasing concentrations
of taurolidine resulted in morphological changes including
cell rounding and detachment. Annexin-V-FITC/PI staining
of OS cells following taurolidine exposure revealed a dose-
dependent increase in the number of apoptotic cells. Similar
results were found with HOS cells (data not shown). Given
that normal bone cells are not as sensitive to the effects of
taurolidine, we also observed that a 24 h treatment of normal
bone cells with 100 μM taurolidine did not induce
significant numbers of apoptotic cells (Fig. 1d).
Taurolidine-induced cytotoxic effects, apoptosis and PARP
are inhibited by the general caspase inhibitor Z-VAD-FMK
PARP cleavage occurs through the activation of caspases, a
family of cysteine acid proteases. Treatment of U2OS cells
with 50, 100 and 200 μM taurolidine resulted in a dose-
dependent increase in PARP cleavage (Fig. 2a). Similar
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results were found with HOS cells (data not shown). In
order to determine whether caspase activation is involved in
PARP cleavage, taurolidine-induced cytotoxicity, apoptosis
and PARP cleavage, U2OS cells were pre-treated for 2 h
with 50 μM of the pan-caspase inhibitor Z-VAD-FMK prior
to taurolidine addition. Twenty-four hours later cell lysates
were subjected to immunoblot analysis and cells were
either subjected to a WST-1 assay or were stained for
annexin-V-FITC/PI to determine apoptotic and necrotic
cells. Pre-treatment with 50 μM Z-VAD-FMK prior to
taurolidine addition significantly inhibited PARP cleavage
(Fig. 2b), decreased taurolidine-induced growth inhibition
of U2OS cells (Fig. 2c) and decreased the number of
annexin-V-FITC positive cells (Fig. 2d).
Taurolidine inhibits adhesion of osteosarcoma cells
in a dose-dependent manner
Taurolidine has been shown to possess anti-adherent
properties and a substantial portion of its anti-bacterial
capability is thought to occur through the inhibition of
micro-organism adhesion [8, 9]. Nestler et al. (2005) [18]
have shown that taurolidine treatment reduces the adhesion
of colon carcinoma cells. In order to determine if
taurolidine could decrease the adhesion of osteosarcoma
cell lines U2OS cells were treated with various concen-
trations of taurolidine and subjected to an adhesion assay.
As shown in Fig. 3a, treatment with taurolidine significant-
ly decreased the number of adherent U2OS cells and similar
Fig. 1 Taurolidine inhibits the growth of OS cell lines and induces
apoptosis. a Taurolidine IC50 values of all cells tested. Cells were
treated with increasing concentrations of taurolidine. Twenty-four or
seventy-two hours later cells were subjected to a WST-1 assay in order
to determine the total viable cells. Values represent mean ± SEM (n ≥
3). Double asterisks signify not tested. b Taurolidine dose response
curve of the OS cell line U2OS (black line), normal bone cells (blue
line) and normal fibroblasts (green line). c U2OS cells were treated
with increasing concentrations of taurolidine. Twenty-four hours later
cells were stained with annexin-V-FITC and PI and visualized for
apoptotic cells. Figures are representative of three independent
experiments. d Normal bone cells were treated with 100 μM
taurolidine. Twenty-four hours later cells were stained for annexinV/
PI and visualized for apoptotic cells
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results were found with HOS cells (data not shown).
Taurolidine treatment also inhibited the adhesion of normal
bone cells (Fig. 3a). However, anti-adherent effects were
only observed when cells were treated with concentrations
of taurolidine higher than those used for U2OS or HOS
cells. Thus, normal bone cells appear to be less sensitive to
the anti-adherent effects of taurolidine.
Taurolidine can be used in combination with doxorubicin
In order to determine whether taurolidine could be used in
combination with a current chemotherapeutic agent used for
the treatment of osteosarcoma, U2OS cells were simulta-
neously incubated with increasing concentrations of doxo-
rubicin and with a concentration of taurolidine that produces
a 10% growth inhibition following a 72 h incubation (15 μM
for U2OS) (Fig. 3b). The combined treatment of taurolidine
and doxorubicin resulted in an additive effect compared to
treatment with either drug alone. Similar results were found
with HOS cells (data not shown).
Discussion
Identification of novel chemotherapeutic agents to improve
the survival rates of osteosarcoma patients are of the utmost
importance. The discovery of novel chemotherapeutic
agents can be an ominous process, as even though a drug
may show activity in vitro, it may face challenges in vivo
due to lack of stability, metabolism or delivery. However,
Fig. 2 Caspase inhibitor prevents taurolidine-induced apoptosis. a
U2OS cells were treated with 0, 50, 100 or 200 μM taurolidine and
resulting cell lysates were subjected to immunoblot analysis for PARP
cleavage and actin. In figures b–d U2OS cells were pre-treated for 2 h
with 50 μM of the general caspase inhibitor Z-VAD-FMK prior to
taurolidine addition. b Twenty-four hours following taurolidine treat-
ment cell lysates were harvested and subjected to western blot analysis.
c Twenty-four hours later cells were subjected to a WST-1 assay to
determine total viable cells. Values represent mean ± SEM (n=3).
d Twenty-four hours later cells were stained with annexin-V-FITC and
PI and visualized for apoptopic cells. Figures are representative of three
independent experiments
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novel chemotherapeutic agents can occasionally be identi-
fied when a compound established for one application is
subsequently examined for anti-neoplastic activity. For
example, taurolidine has been safely used clinically for
over 15 years for the treatment of various surgical
infections and can be safely administered through a number
of routes including intravenous, intrapleural, intraperitoneal
instillation and direct application to wound and bone
cavities [19–21]. For infection, taurolidine is clinically
effective at low mM concentrations and extensive tolerance
investigations have not reported any clinically significant
side effects. When taurolidine was examined for anti-
neoplastic properties it was shown to have efficacy against
a variety of cancer cell lines and several tumor models
(reviewed in [22]). Based on these findings and tauroli-
dine’s previously established clinical safety profile, we
were interested in determining whether taurolidine may
have potential as a novel chemotherapeutic treatment for
patients with osteosarcoma.
In initial studies we examined the effect of taurolidine on
the growth of ten osteosarcoma cell lines possessing various
genetic defects (i.e. mutant p53, defective Rb) and differing
in vivo metastatic potential. All cell lines tested were shown
to be remarkably sensitive to the effects of taurolidine. The
IC50 obtained for OS cell lines are within the range of
previously reported IC50 for ovarian, colon, prostate and
mesothelioma cell lines [10, 14, 18]. Interestingly, all of
these values are approximately 100 times lower than the
concentrations used clinically for the treatment of infection.
A number of reports have stated that the effect of
taurolidine is tumor cell specific and that normal cell lines
and stem cells are not affected by taurolidine treatment [10,
14]. However, few reports have directly examined or
demonstrated the effect of taurolidine on normal cells. In
2001, Calabresi et al. reported that taurolidine inhibited the
growth of NIH-3T3 (mouse) fibroblasts but did not induce
apoptosis of these cells [10]. The inhibitory effect of
taurolidine on NIH-3T3 was also found to be reversible
since proliferation resumed following removal of the
compound. In the current study we found that taurolidine
had cytotoxic effects on both normal human fibroblasts and
normal human bone cells. However, compared to OS cell
lines, these cells were far less taurolidine sensitive. These
data suggest that the cytotoxic effect of taurolidine is tumor
specific, which is consistent with previous reports [10, 14].
Consequently, the in vitro effects of taurolidine on
osteosarcoma cells should be achievable in vivo and/or in
a clinical setting with only minor damage to normal bone
cells or fibroblasts.
The effect of anti-cancer agents on tumor cells can be either
cytostatic (i.e. cell growth suppression) or cytotoxic (i.e. direct
toxic effect). The effect of taurolidine on various other tumor
cell lines has previously been shown to be cytotoxic and
associated with a dose-dependent increase in apoptotic cells
[10, 23]. Annexin-V-FITC/PI staining of osteosarcoma cells
after treatment with increasing concentrations of taurolidine
resulted in a dose-dependent increase in AnnexinV positive
cells, and an increase in PI positive cells at higher concen-
trations. In addition, taurolidine treated osteosarcoma cells
displayed dose-dependent cleavage of PARP. These results
confirm that taurolidine induces apoptosis of osteosarcoma
cell lines.
The mechanism by which taurolidine induces apoptosis
of tumor cells has yet to be elucidated despite the fact that
numerous publications have described taurolidine’s apopto-
tic-inducing effect [10, 13, 14]. Detailed studies regarding
the structure, activity and cellular targets of taurolidine that
are involved in initiating apoptosis have been hindered by
the fact that taurolidine rapidly undergoes hydrolysation in
aqueous environments. Furthermore, isolation and quanti-
fication of the relevant intermediate metabolites has proven
to be difficult [10]. Hydrosylation of taurolidine results in
Fig. 3 Effect of taurolidine on adhesion and in combination with
Doxorubicin. a U2OS cells (filled square) and normal bone cells
(filled triangle) were treated with increasing concentrations of
taurolidine and subjected to an adhesion assay. Values represent mean
± SEM (n=3). b U2OS cells were treated with either increasing
concentrations of doxorubicin alone (filled square) or in combination
with 15 μM taurolidine (filled triangle). Seventy-two hours later cells
were subjected to a WST-1 assay in order to determine the total viable
cells. Values represent mean ± SEM (n=3)
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the production of the metabolites possessing reactive
methylol groups [22]. Previous studies have reported that
the methylol groups interact with bacteria cell wall
components such as lipopolysaccharides (LPS) to induce
taurolidine’s anti-bacterial effects including loss of patho-
genecity, inability to undergo mitosis and reduced adher-
ence. Consequently, it has been hypothesized that
taurolidine may interact with components of the cell
membrane such as cell surface receptors in order to initiate
apoptosis. Yet, these receptors remain to be identified.
However, it is known that taurolidine-induced apoptosis
involves activation of the caspase cascade [23]. Likewise,
in the current study we demonstrated that pre-treatment
with the general caspase inhibitor Z-VAD-FMK inhibited
the effects of taurolidine on cell growth and morphology
and prevented taurolidine-induced apoptosis and PARP
cleavage. These findings confirm that taurolidine-induced
apoptosis of osteosarcoma cells is also caspase mediated.
The formation of metastatic lesions is a complex process
that involves a series of sequential steps that include
intravasation of cells into the circulation, cell survival in
the circulation, arrest of cells in a new organ, cell
adherence, extravasation of cells into the surrounding
tissue, the initiation of growth and vascularization of the
metastatic lesion [24]. Approximately 10–20% of osteosar-
coma patients have detectable metastatic lesions at the time
of diagnosis while 80% have micrometastasis [25, 26].
Death from osteosarcoma typically results from respiratory
failure due to progressive pulmonary metastases. Inhibition
of any of the steps involved in metastases obviously would
be of great benefit to osteosarcoma patients. Taurolidine has
previously been demonstrated to possess anti-adherent
properties. Classically, taurolidine was known to inhibit
the adherence of bacteria and fungi microorganisms [8, 9],
which aids in its ability to treat infections. More recently
taurolidine has been shown to decrease the adherence of
colon carcinoma cells [18]. Similarly, we were able to
demonstrate that treatment with taurolidine results in
decreased adhesion of osteosarcoma cells. The effect of
taurolidine on osteosarcoma patients could potentially be
two-fold, by decreasing primary tumor burden and meta-
static lesions through direct cytotoxic effects and by
reducing metastatic tumor cell seeding via the prevention
of adherence. Based on the fact that taurolidine has
previously been safely applied to bone for treatment of
infection, direct application of taurolidine following surgi-
cal resection of osteosarcoma tumors may also be consid-
ered as a route of administration in order to decrease
adherence of any cells that have escaped resection and to
prevent primary site recurrence.
Current EURAMOS chemotherapeutic treatment regi-
mens for osteosarcoma patients begin with ten weeks of
pre-surgical treatment with doxorubicin, cisplatin and
methotrexate. Following surgery patients are randomized
for post-surgical treatment according to their histological
response to pre-surgical chemotherapy treatment. Post-
surgical treatment for good responders typically involves
doxorubicin, cisplatin and methotrexate with or without
interferon-alpha maintenance therapy while poor respond-
ers receive doxorubicin, cisplatin and methotrexate with or
without inclusion of etoposide, ifosfamide and interferon-
alpha cycles. New treatment options must either replace
existing therapies or must be shown to be compatible with
previously established regimens. In this study we examined
the compatibility of taurolidine in combination with
doxorubicin. The effects of taurolidine were shown to be
additive with doxorubicin and thus, in vitro taurolidine
appears to be relatively compatible with one of the main
agents used for treatment of osteosarcoma and promotes
clinical attractiveness for use in the treatment of osteosar-
coma. However, the clinical effects of taurolidine when
used either alone or in combination with current regimens
will have to be established clinically with particular
attention focused on synergistic and subadditive effects
when used in combination.
The results of the current study suggest that taurolidine
possesses potent anti-neoplastic activity against osteosarcoma
cell lines and may have potential as a novel OS chemother-
apeutic agent. As such, in vivo studies investigating the
ability of taurolidine to reduce primary tumor burden and
metastases in an osteosarcoma mouse model are underway.
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